Retatrutide, by Soma Chems , is attracting considerable attention as a innovative therapy for metabolic management . This dual-action drug merges the mechanism of a GLP-1 receptor agonist and a GIP receptor stimulant, designed to not only promote weight loss but also target associated metabolic issu